PeerView Oncology & Hematology CME/CNE/CPE Video Podcast - Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment

Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment

10/11/21 • 51 min

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severity grading models to determine the presence and severity of organ dysfunction in patients with a VOD/SOS diagnosis, Recommend appropriate team management options for adult and pediatric patients with VOD/SOS in the post-HCT setting.

Previous Episode

undefined - R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy

Go online to PeerView.com/WST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of pharmacy experts in multiple myeloma management discusses the latest evidence on novel antibody and CAR-T options and link key take-homes from the data to core aspects of pharmacy practice, from minimizing adverse events/drug interactions to educating patients and staff while addressing other pharmacy considerations. Upon completion of this accredited CE activity, participants should be better able to: Identify the current treatment role and regulatory status of novel antibodies and cell-based therapy for multiple myeloma, Summarize efficacy and safety evidence related to the use of CD38, SLAMF7, and BCMA-targeting antibodies and BCMA CAR-T therapy in newly diagnosed and relapsed multiple myeloma, Develop educational plans for staff and patients surrounding safety, dosing, and potential drug interactions associated with novel antibodies and cell therapy in multiple myeloma, Apply team-based management strategies for the integration of novel antibodies and cell therapy into existing treatment protocols for multiple myeloma, including addressing formulary concerns or developing intrainstitutional therapeutic algorithms.

Next Episode

undefined - Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care

Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care

Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, for patients with advanced biliary cancers, Apply practice-changing clinical trial evidence to personalize the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics.